Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM796RI)

Drug Name

ZYAN1 Drug Info

Synonyms

Desidustat; 1616690-16-4; UNII-Y962PQA4KS; Y962PQA4KS; 1,2-dihydroquinoline-3-carbonyl]glycine; N-[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-; 2-(1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetic acid; ZYAN1 compound; Desidustat [INN]; SCHEMBL15846922; BCP29692; EX-A2999; s9699; ZB1514; CS-8034; BS-16050; HY-103227; A16921; 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid; Glycine, N-((1-(cyclopropylmethoxy)-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl)carbonyl)-; N-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine

Indication

Disease Entry	ICD 11	Status	REF
Anaemia	3A90	Phase 1	[1]

Cross-matching ID

PubChem CID: 75593290
CAS Number: CAS 1616690-16-4
TTD Drug ID: DM796RI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HIF-prolyl hydroxylase (HPH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclopirox	DMN5T2A	Cutaneous candidiasis	1F23.14	Approved	[3]
AKB-6548	DM2EJM3	Anaemia	3A90	Phase 3	[4]
JTZ-951	DM8FSPV	Anaemia	3A90	Phase 3	[5]
BAY 853934	DM407I6	Anaemia	3A90	Phase 3	[6]
FG-2216	DM7RYL4	Kidney disease	GC2Z	Phase 2	[7]
DS-1093	DM42KZW	Anemia	3A00-3A9Z	Phase 1	[8]
JNJ-42905343	DMCNBHY	Anaemia	3A90	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HIF-prolyl hydroxylase (HPH)	TTJQFBG	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.
2	Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	DOI: 10.1038/nrd4422
5	DOI: 10.1038/nrneph.2015.82
6	Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
7	Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
8	Company report (Daiichisankyo)
9	Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.